OR WAIT 15 SECS
Industry veteran Loewald tapped to head CDMO Cambrex.
Cambrex has announced on June 18, 2020 that Tom Loewald has been named chief executive officer and a member of the company’s board of directors, effective Sept. 7, 2020.
On June 2, 2020, the company announced the retirement of CEO Steven Klosk on June 30, 2020, after 28 years with the company. In addition, the company announced that Shawn Cavanagh was stepping down as president, chief operating officer, and member of the board of directors but will be a strategic advisor to the incoming CEO and board of directors for an initial 12-month period.
Loewald currently is president of the flexibles division of ProAmpac, a flexible packaging manufacturer and serves on the board of directors of Harvard BioScience, a manufacturer of solutions to advance life science.
“Cambrex has a phenomenal reputation for providing unmatched expertise, innovation, and customer service across the entire drug lifecycle, and I am thrilled to be joining the company at a time when bringing therapeutics to patients across the globe is more important than ever,” said Loewald in a June 18 press statement. “I am eager to get to work, alongside the talented leadership team, to further solidify the company’s position as a leader in the CDMO market.”
Wayne Hewett, chairman of the board of directors, said, “Tom’s deep knowledge of life sciences and manufacturing, and strong commercial, operating, and financial focus, make him the ideal leader for Cambrex as we approach this phase of accelerated growth. We are confident that he will be an excellent fit for the company’s customer-centric culture and look forward to supporting him and the entire team on the exciting road ahead.”